(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Which Countries Would Suffer Most in a Global Energy Shutdown? This Study Has Answers - 2Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
- 3Phonetic Associations: A Survey of \Interfacing Worldwide People group\ Language Trade Application
- 4Language Learning Stages: Which One Gets Your Vote?
- 5The most effective method to Arrange a Higher Medical caretaker Pay During Your Next New employee screening
- Vote In favor of Your Favored Kind Of Attire
- 10 Famous Frozen yogurt Flavors All over The Planet
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- 3 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
- Step by step instructions to Show Children the Significance of Appropriate Handshaking
- Find the Abilities Required for Advanced Advertising Position
- Figure out How to Recognize Early Indications of Depressions
- Guaranteeing Quality Medical care with Federal medical care Benefit Plans.
- This Tiny Neon Frog Dwells in the Clouds
